X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Ghana Gives Go Ahead To Oxford University Malaria Vaccine

Content Team by Content Team
14th April 2023
in FDA Approvals, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

A malaria vaccine called R21/Matrix-M, which was developed in collaboration with the University of Oxford as well as a manufacturer of vaccines and immunological products from India, has been given the licence to be used in Ghana by the Food and Drugs Authority over there.

The vaccine, which leverages adjuvant technology from one of the leading US biotech companies in this domain, has been awarded a licence to be used across the country.

With this, it is the first clearance for R21/Matrix-M malaria for use in any specific country. It is well to note that the vaccine has been approved for use among children from 5 to 36 months, a bracket that happens to be at the highest risk of succumbing to malaria.

It happens to be a low-dose vaccine that can be manufactured at a wide scale and that too at a reasonable cost, thereby enabling millions of doses to be supplied to African countries that are already suffering from a significant malaria burden.

Moreover, it has also been demonstrated that the high levels of safety as well as efficacy have been seen in phase 2 trials even for those children who got a booster dose of R21/Matric-M at one year, which was followed by a primary three-dose regime. It is anticipated that this landmark regulatory decision will help Ghanaian and African children thwart malaria.

Adar Poonawalla, who happens to be the CEO of a leading manufacturer of vaccines and immuno-biologics from India, had no doubts about the impact this vaccine would go on to make. As per him, malaria happens to be a life-threatening disease that affects disproportionately the most susceptible populations across society, thereby being a leading cause of death among children.

He added that coming up with a vaccine to massively impact this enormous disease burden was indeed extraordinarily challenging. He added that they happen to be committed to their vision of health for all, thereby making sure of equal access to vaccines for populations across the world.

Adrian Hill, Professor and Director at the Jenner Institute at the Nuffield Department of Medicine under the gamut of the University of Oxford, said that this marks the end of 30 years of malaria vaccine research undertaken by Oxford with the provision as well as design of a high-efficacy vaccine that can get supplied at an appropriate scale across the countries that need them the most.

He also went on to congratulate the clinical trial partners in Africa who could generate the dataset that supported the safety as well as the efficiency of the vaccine among children.

John Jacobs, the president and CEO of the US biotechnology company involved in the research, said that they are thrilled that this Matrix-M adjuvant has contributed towards the success of this much-needed and promising malaria vaccine. He added that it happens to be their intent to unlock the potential of their adjuvants both in the short and long term to consistently enhance public health.

Previous Post

Research Pins Down New Target To Get Rid of Blood Cancer

Next Post

New Targeted Cancer Treatment Therapies Scouted By Singapore

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

New Targeted Cancer Treatment Therapies Scouted By Singapore

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In